Form 4 for GNLX GENELUX Corp
Accepted 2023-08-22 00:00:00 ET · period of report 2023-08-18 · accession 0001209191-23-046879 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-22 | 2023-08-18 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $23.73 | -3,265 | 155.7K | -2% | -$77.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-18 | S | D | 3,265 | $23.73 | 155,735 | D | — | — | (F1) Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. (F2) The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |